EUVIMEDEUVIMED entdecken
Open Access

Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications

Lu Cao, Xiaoyu Dong iD, Fuzhong Chen iD, Guangjuan Li, Jiale Fang, Zhijun Han iD, Junhong Wang iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.036170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Lu Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology The First Affiliated Hospital of Nanjing Medical University Nanjing China. Hauptthemen laut MEDLINE: Heart Failure, Pyruvate Kinase, Ventricular Function, Left. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK‐M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF). Methods and Results We conducted a prospective investigation involving 222 patients with HF and 103 control subjects, measuring PK‐M2 concentrations using ELISA. The primary outcome, assessed over a median follow‐up of 2 years (interquartile range: 776 to 926 days), was the time to the first occurrence of either rehospitalization for worsening HF or cardiovascular death. Patients with HF had higher PK‐M2 levels than controls (17.4±4.1 versus 7.8±2.3 U/mL, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePyruvate KinaseVentricular Function, LeftHumansMaleFemaleBiomarkersAgedMiddle AgedProspective StudiesPrognosisStroke VolumePatient ReadmissionCase-Control StudiesEnzyme-Linked Immunosorbent AssayNatriuretic Peptide, BrainUp-RegulationSeverity of Illness IndexPredictive Value of TestsRisk FactorsTime FactorsDisease ProgressionPeptide Fragments

Stichwörter der Autor:innen

biomarkerheart failurepyruvate kinase M2short‐term prognosis

Substanzen

BiomarkersPyruvate KinaseNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide Fragments

Autor:innen und Institutionen

  • Department of Cardiology The First Affiliated Hospital of Nanjing Medical University Nanjing China.
  • Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine Shanghai China.
  • Department of Cardiology The Friendship Hospital of Ili Kazak Autonomous Prefecture Yining China.
  • Department of Clincal Research Center Jiangnan University Medical Center Wuxi Jiangsu Province China.
  • Department of Cardiology Liyang People's Hospital Liyang China.

ORCID-Profile: Xiaoyu Dong, Fuzhong Chen, Zhijun Han, Junhong Wang

Zitieren

APA

Cao, L., Dong, X., Chen, F., Li, G., Fang, J., Han, Z., & Wang, J. (2025). Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036170

Vancouver

Cao L, Dong X, Chen F, Li G, Fang J, Han Z, et al. Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.036170

BibTeX
@article{Cao2025,
  author = {Cao, Lu and Dong, Xiaoyu and Chen, Fuzhong and Li, Guangjuan and Fang, Jiale and Han, Zhijun and Wang, Junhong},
  title = {Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.036170}
}
Kostenlos starten →